Quarterly ResultMay 6, 2026, 04:22 PM
Quantum Biopharma Q1 Net Loss Widens to $13.75M; Liabilities Surge
AI Summary
Quantum Biopharma Ltd. reported a widened net loss of $13,753,564 for the first quarter of 2026, compared to $8,739,881 in the same period last year. Total liabilities surged to $16,345,974 from $6,058,294, primarily due to new warrant and derivative liabilities, leading to a significant decrease in shareholder equity. The company continues its biopharmaceutical R&D, including Lucid-MS and Unbuzzd, and has expanded its treasury management into cryptocurrencies, which incurred an unrealized loss this quarter.
Key Highlights
- Net loss widened to $13,753,564 for Q1 2026, compared to $8,739,881 for Q1 2025.
- Basic and diluted net loss per share was $(3.06) for Q1 2026, an improvement from $(3.53) for Q1 2025.
- Total assets increased to $14,926,075 as of March 31, 2026, from $11,160,909 at December 31, 2025.
- Total liabilities significantly increased to $16,345,974 as of March 31, 2026, from $6,058,294 at December 31, 2025.
- Equity attributable to shareholders decreased to $595,226 as of March 31, 2026, from $6,924,475 at December 31, 2025.
- Cash and cash equivalents rose to $4,341,908 as of March 31, 2026, from $1,905,357 at December 31, 2025.
- Digital assets increased to $5,468,067 as of March 31, 2026, with an unrealized loss of $1,244,943 for the quarter.
- Loss in fair value of derivative liabilities and warrant liability was $6,954,836 for Q1 2026.